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Low-grade fibromyxoid sarcoma (LGFMS) and hybrid sclerosing epithelioid fibro-
sarcoma (SEF)/LGFMS have a low potential for recurrence (10%) and metastasis 
(5%) but they are notorious for late occurring metastases. The aim of this study 
was to evaluate the outcome of LGFMS and review similar cases reported in the lit-
erature.
We retrospectively evaluated 24 LGFMS operated at a single Institution. All cases 
were histologically revised. Mean age was 34 years (range, 8 to 74). Two cases pre-
sented areas of SEF (hybrid tumours). 
Three patients presented with metastasis at diagnosis. A strong cytoplasmic stain-
ing for MUC4 antibody was found in the majority of neoplastic cells. RT-PCR 
was feasible in 6 cases and it detected the presence of FUS-CREB3L2 fusion gene 
chimeric transcript. 
Mean follow-up was 44 months (range, 6 to 217). Two patients developed lung 
metastasis after 9 and 26 months respectively. 
Low-grade fibromyxoid sarcoma has a various histopathologic spectrum with few 
cases of LGFMS that share histopathologic resemblance with SEF, thereby reinforc-
ing a possibility of a link within these two. It is of paramount importance an ac-
curate and extensive sampling and examination of the whole specimen, in order to 
identify higher risk patients.
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Introduction
Low-grade fibromyxoid sarcoma (LGFMS), also 
called Evans tumour, is a rare sarcoma that typically 
affects young adults and children. It is characterized 
by an indolent clinical course [1, 2, 3].
In some cases, more or less extensive areas rem-
iniscent of sclerosing epithelioid fibrosarcoma (SEF) 
can be seen in combination with LGFMS areas: such 
tumours are known as hybrid SEF/LGFMS [4].
Although LGFMS has a much lower potential 
for recurrence (10%) and metastasis (5%) than SEF 
(> 50%) within the first 5 years, it is notorious for 
late occurring metastases [1]. Apart from tumour size 
and location, no strong predictive markers of metas-
tasis have been identified [4, 5, 6].
Low-grade fibromyxoid sarcoma consists of slen-
der spindle cells with long, narrow, delicate and 
mostly non-branching cell processes, embedded in 
a variable amount of collagenous stroma. On histo-
logical examination, LGFMS can be circumscribed or 
infiltrative, and is predominantly composed of bland- 
appearing spindle cells with small, angulated nuclei 
with inconspicuous nucleoli and scant, wispy cyto- 
plasm [3]. Immunohistochemically, LGFMS character-
istically shows strong and diffuse granular cytoplasmic 
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immunoreactivity with MUC4. It is highly sensitive 
for LGFMS [6].
However, the heterogeneous histological appear-
ance makes the diagnosis challenging. 
The majority of LGFMS cases have been shown to 
harbour a translocation between chromosome 7 and 16, 
resulting in a chimeric fusion protein derived from 
the fused in sarcoma (FUS) gene of chromosome 
16p11 and the cAMP responsive element-binding 
protein 3-like 2 (CREB3L2) gene of 17q33 [3, 7]. 
A minority of cases have been shown to display 
a FUS-CREB3L1 [8].
Surgical excision with clear resection margins is 
the first line treatment option.
Maretty-Nielsen et al. [9] postulated that LGFMS 
is not very chemo- or radiosensitive due to its low nu-
clear grade and infrequent mitotic activity.  Howev-
er, another study by Cesne et al. [10] suggested that 
trabectedin could offer some benefit in translocation- 
related soft tissue sarcomas such as LGFMS. 
The aim of this study was to evaluate the out-
come of LGFMS and review similar cases reported in 
the literature.
Material and methods
From January 1999 to June 2018 a total of 28 pa- 
tients received diagnosis of Evans tumour or hybrid 
SEF/LGFMS of the extremities at a single Institu-
tion (Rizzoli Orthopedic Institute, Bologna, Italy). 
All cases were histologically revised and classified 
according to the 2013 World Health Organization 
classification of STS [11] by experienced sarcoma 
pathologists of our Institute (AR). Immunohisto-
chemical analysis with MUC4 antibody (Mouse 
Monoclonal Antibody, clone 8G7, Santa Cruz Biotech-
nology, 1 : 300 dilution) was done on all cases. Reverse 
transcriptase-polymerase chain reaction (RT-PCR) 
was carried out to detect t(11;22) EWSR1-CRE-
B3L1, t(7;22) EWSR1-CREB3L2, t(7;16) EWSR1- 
CREB3L2 and t(11;16) EWSR1-CREB3L1 using 
RNA extracted from the frozen specimens, as previ-
ously described [12]. Fluorescent in situ hybridization 
(FISH) analysis for EWSR1 and FUS break-apart was 
performed to confirm the results of RT-PCR.
Four cases had a follow-up shorter than 6 months 
and were therefore excluded. 
Tumour size was assessed on pre-operative MRI 
using the larger diameter as a reference and depths 
were divided into superficial (above the fascia) and 
deep (below the fascia). All patients underwent oper-
ation in order to obtain limb-sparing, function-spar-
ing surgery with negative surgical margins, accord-
ing to the Enneking classification [13].
The use of radiotherapy (RT) and chemotherapy 
(CT) was decided at the discretion of a multidisci-
plinary team (orthopedic surgeon, radiotherapist and 
oncologist). Radiation therapy and chemotherapy 
were administered according to STS guidelines [14].
A descriptive study is presented and data are pre-
sented in total frequencies and percentages. All anal-
ysis was completed using the Statistical Package for 
Social Science (IBM Corp. Released 2013. IBM SPSS 
Statistics for Windows, Version 22.0. Armonk, NY: 
IBM Corp.).
Informed consent was obtained by all the patients 
involved in the study.
All performed procedures were in accordance with 
the ethical standards of the local ethic committees 
and with the Helsinki Declaration of 1975, as revised 
in 1983. 
Results
Of 24 cases of LGFMS (Table I), two cases (n. 12 and 
21) presented some areas of SEF and were identified 
as hybrid tumours. Eight patients were male, 16 were 
female. Mean age was 34 years (range, 8 to 74).
Location-wise, most cases were deep-seated (18). 
Most of the tumours (15) were in the lower limb, 
6 were in the pelvic girdle, one in the upper limb and 
one in the shoulder girdle.
Eleven LGFMS were small (< 5 cm), 11 were be-
tween 5 and 10 cm and two larger than 10 cm. Three 
patients presented with metastasis at diagnosis (two 
to the lungs and one to the spine). Histologically, ver-
tebral metastasis of case 21 (hybrid tumour on pri-
mary lump) presented only features of SEF.
Apart from one patient in which an amputation 
was required, all other patients underwent excision 
of the tumour. Among these, 20 patients underwent 
wide surgical excision while three had marginal mar-
gins.
Macroscopically, all but two cases were well cir-
cumscribed with a white, fascicular appearance with-
out areas of necrosis on cut section (Fig. 1A). Two 
cases showed infiltration of adjacent tissue. Morpho-
logically, 8 cases showed “giant rosettes” character-
ized by hyalinixed collagenous nodular structures 
surrounded by palisading rounded or ovoid cells. In 
addition, nine cases evidenced markedly hypocellular 
and sclerotic areas with a misleading fibrotic appear-
ance (Fig. 1B, C). Mitotic activity was low (mean one 
mitosis/10 high power fields) and necrosis was not 
evident in all cases. 
A strong cytoplasmic staining for MUC4 antibody 
was found in the majority of neoplastic cells (Fig. 1D). 
In 6 cases, frozen neoplastic tissue was available 
to extract RNA. RT-PCR was feasible in all these 
6 cases that detected the presence of FUS-CREB3L2 
fusion gene chimeric transcript (Fig. 1E). All the other 
fusion chimeric transcripts examined (EWSR1-CRE-
B3L1, EWSR1-CREB3L2, and EWSR1-CREB3L1) 
were not found.  FISH analysis confirmed the RT-PCR 
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Fig. 1. A) An example of the macroscopy of a low-grade fibromyxoid sarcoma, showing a lobulated, glistening, leio-
myoma-like, whitish mass. B, C) On hematoxylin and eosin, the tumor consists of very blande spindle cells embed-
ded in a densely collagenous background, showing hypocellular and hypercellular areas (B: 100 × of magnification; 
C: 200 × of magnification). D) A strong immunohistochemical expression of MUC4 is evident in the majority of neoplas-
tic cells (200 × of magnification). E) Chimeric FUS/CREB3L2 fusion transcripts, involving t(7;16) (q33;p11), is found in 
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results. FUS gene rearrangement was identified in 
the form of split signals in contrast to normal fused 
signals in all 6 cases examined. Conversely, EWSR1 
gene rearrangement was not found in any cases. 
Mean follow-up was 44 months (range, 6 to 217). 
Three patients (n. 1, 21 and 23) developed lung me-
tastasis after 9, 26 and 45 months respectively. One 
of these (hybrid tumour) already presented vertebral 
metastasis. Local recurrence was observed in only 
one patient (n. 23) after 83 months. Overall, at last 
follow up twenty patients are alive with no evidence 
of disease. One patient (n. 1) is alive with no evidence 
of the disease after lung metastasectomy. Two pa-
tients (n. 21 and 22) who had metastasis at diagnosis 
died of the disease after 19 and 11 months, respec-
tively. Two patients (n. 23 and 24) affected by syn-
chronous or metachronous lung metastasis are still 
alive with slow progression of the disease after 191 
and 69 months, respectively.
Among four patients with metastasis, only one was 
a hybrid case containing areas of SEF in the specimen.
Discussion
Low-grade fibromyxoid sarcoma is a low-grade 
distinctive variant of fibroblastic neoplasm with 
a metastasizing potential and, occasionally, long in-
tervals between tumour presentation and metastasis. 
In the present series only two out of 24 tumours 
presented areas of SEF. All tumours were extensively 
sampled and examined for identification of areas re-
sembling SEF, including polygonal cells with eosino-
philic to clear cytoplasm, arranged in cords and nests 
within a densely hyalinized stroma associated with 
a high mitotic activity and foci of tumoral necro-
sis [4, 5]. The mere presence of epithelioid cells was 
disregarded as a criterion for SEF-like morphology. 
A much higher proportion of such areas, more than 
50%, would form a criterion for diagnosis of SEF, 
although there is no specific cut-off value for label-
ling pure and mixed SEF [7]. 
One out of two (50%) hybrid tumours presented 
with an aggressive clinical course (both synchronous 
vertebral and metachronous lung metastasis). More-
over, in the specimen of the vertebral metastasis, only 
areas of SEF were found. This might suggest a cells 
clone selection in the metastatic process. Noteworthy, 
only three out of 22 patients (11.5%) with “pure” 
LGFMS developed metastasis (either synchronous or 
metachronous).
Giant rosettes were found in 8 cases. This dis-
tinctive type of LGFMS containing rosettes was first 
described in 1997 [2] but the significance and patho-
genetic mechanisms of the peculiar giant rosettes 
present in this type of fibroblastic neoplasm remain 
unclear. We did not find any correlation of rosettes 
with patients’ prognosis.
Morphologically, because of its bland appearance, 
particularly evident in the cases with prevalent scle-
rotic areas, LGFMS could easily be confused with 
various benign soft tissue tumours, in particular on 
the biopsies, including desmoid fibromatosis, peri-
neurioma, and cellular myxoma, as well as other 
low-grade sarcomas, especially low-grade malignant 
peripheral nerve sheath tumour and low-grade myx-
ofibrosarcoma. Our series confirms that MUC4 is 
the best available marker for this tumour type be-
cause of very high accuracy to recognize LGFMS. 
Molecular analysis (RT-PCR and FISH) detecting 
FUS-CREB3L2 fusion gene chimeric transcript and 
FUS gene rearrangement confirms and supports 
the morphological and immunohistochemical results. 
It is interesting to observe that in all 6 cases examined 
with RNA available extracted from frozen tissue we 
found FUS gene rearrangement. Indeed, the propor-
tion of LGFMS cases positive for the FUS break-apart 
reported in the existing literature varies considerably. 
Panagopoulos et  al. [8] reported 12 positive cases 
out of 59 LGFMS patients; however, other studies 
have shown proportions of positive cases ranging 
from 81.1% to 96% [15, 16]. The large variation in 
the proportion of positive cases in different studies 
might be explained by differences in local practices 
and inclusion criteria. While the diagnosis of LGFMS 
“traditionally” is made based on the characteristic 
histological appearance and immunohistochemical 
features, some centres use the FUS break apart anal-
ysis as a part of the diagnostics, resulting in a, not 
surprisingly, variable proportion of positive cases.
Surgery, including wide excision with clear resec-
tion margins, remains the mainstay of treatment. In 
fact, due to the low grade of malignancy and there-
fore the low mitotic rate, LGFMS is not expected to 
be very chemo- or radiosensitive. 
Recurrence and metastasis rate in the present 
study are similar to those previously reported by 
Folpe et al. [17]. We report a 4% rate of  local recur-
rence (1 out of 24). Metastasis rate considering both 
synchronous and metachronous) was 21%. These 
data are similar to those reported a local recurrence 
rate of 9%, metastasis rate of 6%, and 1% of patients 
dying of LGFMS with a median of 24 months of fol-
low-up. Guillou et al. [16] reported a smaller series 
with longer follow-up. Their recurrence rate and me-
tastasis rate were both 21% for those cases present-
ing with only local disease, with an overall metastasis 
rate of 27%. However, in Evans’ most recent com-
prehensive study [1] of 33 LGFMS cases with long 
term follow-up (mean of 14 years), half of the pa-
tients developed metastasis and 42% died of disease. 
Thus, the potential for late recurrences and metastat-
ic spread is high, necessitating long-term follow-up 
for all patients with LGFMS. 
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As for soft tissue sarcomas in general, superficial 
LGFMS has generally been associated with a good 
prognosis, which is better than that for deep-seated neo-
plasms [15]. All patients who developed metastasis in 
the present series had deep-seated tumours. However, 
Evans [1] reported that also small tumour size might 
represent a favourable prognostic factor in LGFMS. 
Low-grade fibromyxoid sarcoma has a diverse his-
topathologic spectrum with a few cases of LGFMS 
which share histopathologic resemblance with SEF, 
thereby reinforcing a possibility of a link within these 
two. Even though even LGFMS can develop metas-
tasis, it is of paramount importance an accurate and 
extensive sampling and examination of the whole 
specimen, in order to identify higher risk patients.
The authors declare no conflict of interest.
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